Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Completes Olympus Dx Buy

NEW YORK (GenomeWeb News) – Beckman Coulter has completed its $780 million acquisition of Olympus' lab-based diagnostics business, the firm announced over the weekend.

Beckman funded the acquisition with $495 million that was raised through the issuance of two, $250 million senior note offerings, and around $240 million from a common stock offering of approximately 4.7 million shares issued to the public at a price of $53 per share.

The Orange County, Calif.-based diagnostics and life science products firm initially announced the deal in February.

"We are confident that the combination of Olympus diagnostics with our business will provide many cross-selling opportunities — the most compelling being promotion of Beckman Coulter's leading immunoassay products to the loyal base of Olympus' chemistry customers," Scott Garrett, Beckman Coulter's chairman, president, and CEO, said in a statement.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.